Organisation paid for research Program year 2025 Source: CMS Open Payments

Quantum Leap Healthcare Collaborative

Neither a doctor nor a teaching hospital

Research payments

$23,526,387

25 payments

Through program year 2025, Quantum Leap Healthcare Collaborative is reported as receiving $23,526,387 in research payments, across 25 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$11,045,443	10
2024	Research	$1,849,276	2
2023	Research	$9,251,168	9
2022	Research	$474,500	1
2021	Research	$506,000	2
2020	Research	$400,000	1

Breakdown

Who paid Research payments · program years 2020–2025

AstraZeneca UK Limited $11,564,091 4 payments
AstraZeneca Pharmaceuticals LP $4,965,377 5 payments
Pfizer Inc. $4,253,660 7 payments
Stemline Therapeutics Inc. $1,837,259 6 payments
Genentech, Inc. $906,000 3 payments

Studies the money was for Research payments · program years 2020–2025

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis) An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy $11,564,091 4 payments
Preispy Trial Preinvestigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis A Phase Iib Platform Trial $4,253,660 7 payments
I-SPY 2 2 Evolving the I-SPY 2 TRIAL and Progress in Learning How to Adapt Therapies for Each Patient to Optimize Outcome $4,240,877 3 payments
Stml-Ist-Qlhc $1,837,259 6 payments
I Spy Covid Trial An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements $906,000 3 payments
Olaparib AZD2281 Platform Expansion $724,500 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.